The digital endpoint solution your pharma clients need
When your pharmaceutical or gene therapy clients ask about digital endpoints for CNS trials, NeuroQuantix gives you a validated, published, regulation-ready answer, backed by data you can reference directly in your advisory.
Strengthen your advisory with data-backed recommendations
Your clients rely on your expertise to select the right tools for their clinical programs. When you recommend NeuroQuantix, you are recommending a platform grounded in 300+ peer-reviewed studies with a published scoping review in Movement Disorders Clinical Practice.
We provide consultants with briefing packages, technical summaries, and effect size comparisons that you can incorporate directly into your client presentations and regulatory strategy documents.
Published Evidence Base
Scoping review of 120 studies (1,407 citations screened). Every claim backed by published data with DOI references.
Measurement Sensitivity Story
How continuous kinematic measurement complements traditional clinician-rated scales like UPDRS and TETRAS — framed for client presentations.
Regulatory Pathway Clarity
COA/DDT qualification pathway and 510(k) predicate device analysis. Clear regulatory strategy your clients can evaluate.
Smaller-Cohort Feasibility
Higher measurement precision enables powered studies with smaller cohorts — translatable directly into timeline and cost savings for your client.
Reference materials for your advisory
Detailed effect-size data, regulatory pathway analysis, and head-to-head comparisons across published literature are available on request as part of the consultant briefing package.
Consultant Briefing Package
Comprehensive technical brief covering the platform, evidence base, published effect sizes with citation provenance, regulatory pathway analysis, and integration considerations for your client engagements. Formatted for inclusion in advisory deliverables.
How we work with consultants
Briefing Package
We provide a comprehensive technical brief covering the platform, evidence base, regulatory pathway, and effect size data, formatted for client presentation.
Client Introduction
When your client is ready, we engage directly with their clinical team to scope integration, discuss trial-specific endpoints, and provide a detailed technical proposal.
Ongoing Collaboration
We support your advisory role with updated data, regulatory developments, and endpoint strategy input throughout the client engagement.
Resources for your advisory
NeuroQuantix Technical Data
Platform capabilities, published evidence synthesis, and regulatory pathway documentation for your client presentations.
FaceWise Assessment
Memory consolidation measurement for cognitive decline trials. A complementary product for AD programs.
Regulatory Strategy
COA/DDT qualification and global regulatory navigation that supports your recommendations.
Frequently Asked Questions
What digital endpoint evidence can consultants present to pharma clients?
NeuroQuantix provides a published scoping review of 120 studies, comparative analyses showing how digital kinematic measurement complements UPDRS and TETRAS, and qualitative discussion of the smaller-cohort feasibility that continuous measurement enables. The briefing package includes DOI references for client-facing materials.
How does the consultant partnership work?
We provide a comprehensive briefing package with technical data, effect size comparisons, and regulatory pathway documentation. When your client is ready, we engage directly with their clinical team to scope integration and provide a detailed technical proposal.
What indications does NeuroQuantix cover for consultant recommendations?
NeuroQuantix covers 23 neurological conditions including essential tremor, Parkinson disease, dystonic tremor, cerebellar ataxia, functional tremor, orthostatic tremor, and tardive dyskinesia. The platform applies 82 diagnostic rules across 397 kinematic metrics.
What regulatory pathway documentation is available for client presentations?
COA/DDT qualification pathway analysis, 510(k) predicate device mapping, and multi-jurisdictional regulatory strategy documentation covering FDA, EMA, and Health Canada. Formatted for inclusion in client advisory deliverables.
Can consultants white-label NeuroQuantix in their advisory work?
Yes. Engagement models include white-label scientific advisory, joint client presentations, and ongoing technical consultation. The goal is to strengthen your advisory with specialized CNS measurement expertise while maintaining your client relationship.
Request a consultant briefing
Get the technical brief, effect size comparisons, and regulatory pathway documentation you need to recommend NeuroQuantix to your clients with confidence.
Request Briefing Package